Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Investor Presentation (September 2014)
16 slides from Scorpius's investor presentation, Sep 8, 2014
Slide 1: Corporate Presentation September 2014
Corporate Presentation September 2014
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: Next-Generation Immunotherapy Company
Next-Generation Immunotherapy Company * 1974: Discovery of MHC I’s ability to stimulate tumor-specific CD8+ T cell response Heat Biologics – ImPACT Therapy Proprietary allogeneic immunotherapy No patient tumor requiredPan-AntigenicExclusive CD8+ response seeks out and destroys targeted cancer ImPACT
Slide 4: HTBX Overview
HTBX Overview Next-generation ImPACT® cancer immunotherapy unleashes immune system against a wide range of cancersIPO on June 24, 2013Two ongoing multicenter phase 2 clinical trials with multiple fully-funded near-term catalystsBladder Cancer - Phase 1/2 Non-small cell lung cancer (NSCLC) - Phase 2
Slide 5: World-Renowned Advisory Boards
World-Renowned Advisory Boards * Scientific Advisory Board Clinical Advisory Board
Slide 6: ImPACT Therapy vs. Other Cell-Based Immunotherapy Approaches
ImPACT Therapy vs. Other Cell-Based Immunotherapy Approaches Criteria/Benchmarks ImPACT® Therapy Other Allogeneic Autologous Cell-based Pan-antigen delivery (known and unknown) Some Some Targeted delivery of antigens to APC in vivo Exclusive cytotoxic CD8+ T cell response Some Dual antig
Slide 7: ImPACT Modified Cell Vaccine
ImPACT® Modified Cell Vaccine Injection into Patient ImPACT® Therapy ImPACT® Cell Killer T-Cell * Choose cancer of interest Screen and identify representative cancer cell lines Transform these cells into ImPACT® cells to secrete own antigens Mass produce ImPACT® cells as drug to treat all patients I
Slide 8: HS-110 NSCLC Phase 2 Clinical Trial Results
HS-110 NSCLC Phase 1 Clinical Trial Results * Scott Gettinger, Yale Cancer Center, 2014 ASCO annual Meeting Nivolumab NSCLC 2nd Line(BMS PD-1 blocking antibody) HS-110 NSCLC ≥ 2nd line 1 year OS Rate 44% 2 year OS rate 19% Well-tolerated with no overt toxicity Single agent clinical activity in heavi
Slide 9: Immune Response Predictive of Survival
Immune Response Predictive of Survival Responders saw a threefold increase in median overall survival compared to non-responders in the trial, from 4.5 months to 16.9 months Non-Responders Responders >3x Extension of Median OS for Responders 6 12 18 24 30 36 0.25 0.50 1.00 0.75 Proportion Surviving
Slide 10: Phase 2 HS-110/CY Combo NSCLC Design
Phase 2 HS-110/CY Combo NSCLC Design3rd or 4th line * * RegimenLow-dose cyclophosphamide (CY) 50 mg daily for 7 days every 2 weeks for 12 weeks or until progressionHS-110 107 cells weekly for 12 weeks then every 9 weeks until irPD or 12 months, whichever comes firstSample Size123 patients randomized
Slide 11: Bladder Cancer and HS-410 Background
Bladder Cancer and HS-410 Background Currently-available treatments have high failure rate and are poorly toleratedAmong highest lifetime treatment cost per patient of any cancer due to a high recurrence rateOpportunity to treat patients with minimal residual diseaseNo new drug for this patient popu
Slide 12: Phase 1/2 HS-410 NMIBC Bladder Cancer Design
Phase 1/2 HS-410 NMIBC Bladder Cancer Design * RegimenAfter TURBT, placebo or HS-410 (106 or 107 cells per dose) in combination with BCG for 6 weeks followed by 6 weeks of placebo or HS-410 alone then 3 courses of placebo or HS-410 in combination with BCG for 3 weeks at 3, 6, and 12 months after sta
Slide 13: Business Development Strategy
Business Development Strategy * ImPACT Platform PartnershipsStrategy to Partner by indication(s)Use platform for new product discoveryProduct development by partnerClinical Programs (HS-110, HS-410)Partner at/after Phase 2 dataPartner with regional or global rightsMoA complementary with checkpoint i
Slide 14: Milestones and Investment Considerations
* 1H 2014 2H 2014 1H 2015 2H 2015 Revised NSCLC strategyInitiated Phase 1 bladder cancer trialImPACT combination poster presentations Initiate Phase 2 NSCLC Complete Phase 1 bladder Phase 1 bladder initial safety and secondary endpointsInitiate Phase 2 bladder Phase 1 bladder final immune response a
Slide 15: Summary
SummaryClinical Stage Platform Technology Generating Promising Human Data Data to Date Demonstrate: Positive safety profile Powerful, disease-specific immune activation Immune activation corresponds with increased overall survival EncouragingClinical Data Strong Clinical Pipeline Phase 2 NSCLC clini
Slide 16: Living Drug Factories to Treat Cancer
Living Drug Factories to Treat Cancer
Heat Biologics — Investor Presentation (September 2014) on 6ix